

---

## **Table of Contents**

**State/Territory Name:** North Dakota

**State Plan Amendment (SPA) #:** ND-16-0017

This file contains the following documents in the order listed:

- 1) Approval Letter
- 2) CMS 179 Form/Summary Form (with 179-like data)
- 3) Approved SPA Pages

DEPARTMENT OF HEALTH & HUMAN SERVICES  
Centers for Medicare & Medicaid Services  
7500 Security Boulevard, Mail Stop S2-26-12  
Baltimore, Maryland 21244-1850



**Center for Medicaid and CHIP Services**  
Disabled and Elderly Health Programs Group

---

November 1, 2016

Maggie D. Anderson, Executive Director  
North Dakota Department of Human Services  
600 East Boulevard Avenue, Department 325  
Bismarck, ND 58505-0250

Dear Ms. Anderson:

We have reviewed the North Dakota State Plan Amendment (SPA) 16-0017 received in the Denver Regional Office on October 7, 2016. This amendment updates the terms upon which the state intends to collect supplemental rebates from drug manufacturers. North Dakota entered into a supplemental agreement (SRA) with the Sovereign States Drug Consortium (SSCD) on July 1, 2015. Changes to this SRA include the terms upon which the state will collect supplemental rebates on those drugs dispensed to Medicaid Managed Care Organization (MCO) enrollees from drug manufacturers. We are pleased to inform you that the amendment is approved, effective January 1, 2017.

Based upon the information provided, we believe this amendment is consistent with the objectives of the Medicaid program, is designed to increase the efficiency and economy of the Medicaid program and benefits Medicaid beneficiaries. Approval of North Dakota SPA 16-0017 extends only to the North Dakota SRA and attachment templates submitted to the Centers for Medicare & Medicaid Services (CMS) on October 7, 2016. These revised SRA documents will replace the current SRA packet submitted to CMS on September 30, 2015. If changes are subsequently made to the SRA or its attachments, a new SPA and any required documents should be submitted to CMS for review and authorization.



A copy of the CMS-179 form, as well as the pages approved for incorporation into the North Dakota state plan, will be forwarded by the Denver Regional Office. If you have any questions regarding this amendment, please contact Renee Hilliard at (410) 786-2991.

Sincerely,

A black rectangular redaction box covering the signature of John Coster.

John Coster  
Director,  
Division of Pharmacy

cc: Richard Allen, ARA, Denver Regional Office

<b>TRANSMITTAL AND NOTICE OF APPROVAL OF STATE PLAN MATERIAL</b>  <b>FOR: CENTERS FOR MEDICARE AND MEDICAID SERVICES</b>		1. TRANSMITTAL NUMBER:  <b>16-0017</b>	2. STATE  <b>North Dakota</b>
		3. PROGRAM IDENTIFICATION: <b>TITLE XIX OF THE SOCIAL SECURITY ACT (MEDICAID)</b>	
TO: REGIONAL ADMINISTRATOR CENTERS FOR MEDICARE AND MEDICAID SERVICES DEPARTMENT OF HEALTH AND HUMAN SERVICES		4. PROPOSED EFFECTIVE DATE  <b>January 1, 2017</b>	
5. TYPE OF PLAN MATERIAL (Check One):  <input type="checkbox"/> <b>NEW STATE PLAN</b> <input type="checkbox"/> AMENDMENT TO BE CONSIDERED AS NEW PLAN <input checked="" type="checkbox"/> <b>AMENDMENT</b>			
COMPLETE BLOCKS 6 THRU 10 IF THIS IS AN AMENDMENT (Separate Transmittal for each amendment)			
6. FEDERAL STATUTE/REGULATION CITATION: <b>Section 1927 of the Social Security Act (42 USC 1396r-8)</b>		7. FEDERAL BUDGET IMPACT: a. FFY <u>2017</u> (\$ <u>64,000</u> ) b. FFY <u>2018</u> (\$ <u>256,000</u> )	
8. PAGE NUMBER OF THE PLAN SECTION OR ATTACHMENT:  Attachment to Page 4 of Attachment 3.1-B Attachment to Page 5 of Attachment 3.1-A		9. PAGE NUMBER OF THE SUPERSEDED PLAN SECTION OR ATTACHMENT (If Applicable): Attachment to Page 4 of Attachment 3.1-B Attachment to Page 5 of Attachment 3.1-A	
10. SUBJECT OF AMENDMENT:  Amends the North Dakota State Plan to allow negotiation and collection of managed care supplemental drug rebates.			
11. GOVERNOR'S REVIEW (Check One): <input type="checkbox"/> GOVERNOR'S OFFICE REPORTED NO COMMENT <input checked="" type="checkbox"/> OTHER, AS SPECIFIED: <input type="checkbox"/> COMMENTS OF GOVERNOR'S OFFICE ENCLOSED <u>Maggie D. Anderson, Executive Director,</u> <input type="checkbox"/> NO REPLY RECEIVED WITHIN 45 DAYS OF SUBMITTAL <u>Department of Human Services</u>			
12. SIGNATURE OF STATE AGENCY OFFICIAL: 		16. RETURN TO:  <b>Maggie D. Anderson, Executive Director ND Department of Human Services 600 East Boulevard Avenue Dept 325 Bismarck ND 58505-0250</b>	
13. TYPED NAME: <u>Maggie D. Anderson</u>			
14. TITLE: <b>Executive Director, Department of Human Services</b>			
15. DATE SUBMITTED: <b>October 7, 2016</b>			
<b>FOR REGIONAL OFFICE USE ONLY</b>			
17. DATE RECEIVED: <b>October 7, 2016</b>		18. DATE APPROVED: <b>November 1, 2016</b>	
<b>PLAN APPROVED – ONE COPY ATTACHED</b>			
19. EFFECTIVE DATE OF APPROVED MATERIAL: <b>January 1, 2017</b>		20. SIGNATURE OF REGIONAL OFFICIAL: 	
21. TYPED NAME: <b>Trinia J. Hunt</b>		22. TITLE: <b>Acting ARA, DMCHO</b>	
23. REMARKS:			

ON AMOUNT, DURATION AND SCOPEServices

- 12a. In compliance with Section 1902(a)54 and Section 1927 of the Social Security Act the Medical Services Division of the Department of Human Services will cover drugs supplied by those manufacturers participating in the drug rebate program with the federal Centers for Medicare & Medicaid Services (CMS) with the following limitations as defined by the Medical Services Division of the Department of Human Services:
1. Drug Efficacy Study Implementation (DESI) Study drugs as determined by the Food and Drug Administration to be less-than-effective and items that are identical, related, or similar (IRS) will not be allowed for payment.
  2. Experimental or investigational drugs will not be allowed for payment, with the exception of stiripentol (generic, if available; brand if generic is not available) for children if the coverage has been ordered by the child's physician, determined medically necessary by the Department of Human Services, and has been authorized for the specific child's use by the U.S. Food & Drug Administration.
  3. Drugs dispensed in quantities of more than a 34-day supply will not be allowed for payment with the exception of:
    - a. Claims received in which a third party liability has been processed; or
    - b. Claims for unit of use products where the directions are such that the supply will last longer than 34 days.
  4. Drugs identified by the Medical Services division as requiring prior approval and listed in the Pharmacy Provider Manual will not be allowed for payment except in accordance with SSA 1927(d). The following prior authorization requirements, found in section 1927(d)(5) of the Act, are met: The prior authorization program provides a response by telephone or other telecommunication device within 24 hours of a request and the prior authorization program provides for the dispensing of at least a 72-hour supply of a covered drug in an emergency situation.
    - a. Supplemental Rebate Agreements: Certain covered products in accordance with Section 1927 of the Social Security Act may not be among the baseline preferred drugs identified by the State of North Dakota's Drug Use Review Board for various therapeutic classes. The state may negotiate supplemental rebate agreements that would reclassify any drug not designated as preferred in the baseline listing for as long as the agreement is in effect.

In addition, the State has the following policies for the supplemental rebate program for the Medicaid Population:

The state of North Dakota has entered into an agreement with the "Sovereign States Drug Consortium (SSCD)" Medicaid multi-State purchasing pool. In addition to collecting supplemental rebates for fee-for-service claims, the state may, at its option, also collect supplemental rebates for Medicaid member utilization through MCO(s) under an agreement. Funds received from supplemental rebate agreements will be reported to CMS.

The state will remit the federal portion of any supplemental rebates collected. Manufacturers with supplemental rebate agreements are allowed to audit utilization data.

A rebate agreement between the state and a drug manufacturer for drugs provided to the Medicaid program, submitted to the Centers for Medicare & Medicaid Services (CMS) on September 30, 2015 and entitled, "SSDC North Dakota Medicaid Supplemental Rebate Agreement" has been authorized by CMS.

This Agreement may not be amended or modified without the mutual written consent of the parties. Any modification or amendment must be authorized by CMS.

The unit rebate amount is confidential and cannot be disclosed in accordance with Section 1927 (b)(3)(D) of the Social Security Act.

The Medical Services Division may require prior authorization for covered outpatient drugs. Non-preferred drugs are available with prior authorization.

The prior authorization process for covered outpatient drugs will conform to the provisions of Section 1927 (d)(5) of the Social Security Act.

5. Erectile dysfunction drugs will not be allowed for payment.
6. The early refill threshold for non-controlled substance prescriptions is 80%. This can be over-ridden by the pharmacist if:
  - a. They determine it is medically necessary to over-ride the early refill edit; and
  - b. The previous prescription is 50% utilized or more; and
  - c. The pharmacist submits the necessary over-ride codes.

The early refill threshold for controlled substance prescriptions is 85%. Pharmacists must contact Medical Services to discuss medical necessity for controlled substance prescription early refills as well as any non-controlled substance prescriptions that don't meet all three of the above conditions.

Accumulation edits allow a maximum of 10 days of supply accumulation in a rolling six month period for controlled substances and a maximum of 15 days of supply accumulation in a rolling six month period for non-controlled substances. Pharmacists must contact Medical Services to discuss medical necessity for over-rides for accumulation edits.

7. To increase the cost-effectiveness of dispensing habits, quantities of medication may be restricted if the Medical Services Division or the Drug Utilization Review (DUR) Board determines (a) an alternate method of dispensing would be medically appropriate and more cost-effective, or (b) the dose is not a medically accepted dose supported by citations in the compendia described in Section 1927(g)(1)(B)(i) of OBRA '93.
8. Effective January 1, 2006, the Medicaid agency will not cover any Part D drug for full-benefit dual eligible individuals who are entitled to receive Medicare benefits under Part A or Part B.

The Medicaid agency provides coverage (as specified below) for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses to all Medicaid

ON AMOUNT, DURATION AND SCOPEServices

- 12a. In compliance with Section 1902(a)54 and Section 1927 of the Social Security Act the Medical Services Division of the Department of Human Services will cover drugs supplied by those manufacturers participating in the drug rebate program with the federal Centers for Medicare & Medicaid Services (CMS) with the following limitations as defined by the Medical Services Division of the Department of Human Services:
1. Drug Efficacy Study Implementation (DESI) Study drugs as determined by the Food and Drug Administration to be less-than-effective and items that are identical, related, or similar (IRS) will not be allowed for payment.
  2. Experimental or investigational drugs will not be allowed for payment, with the exception of stiripentol (generic, if available; brand if generic is not available) for children if the coverage has been ordered by the child's physician, determined medically necessary by the Department of Human Services, and has been authorized for the specific child's use by the U.S. Food & Drug Administration.
  3. Drugs dispensed in quantities of more than a 34-day supply will not be allowed for payment with the exception of:
    - a. Claims received in which a third party liability has been processed; or
    - b. Claims for unit of use products where the directions are such that the supply will last longer than 34 days.
  4. Drugs identified by the Medical Services division as requiring prior approval and listed in the Pharmacy Provider Manual will not be allowed for payment except in accordance with SSA 1927(d). The following prior authorization requirements, found in section 1927(d)(5) of the Act, are met: The prior authorization program provides a response by telephone or other telecommunication device within 24 hours of a request and the prior authorization program provides for the dispensing of at least a 72-hour supply of a covered drug in an emergency situation.
    - a. Supplemental Rebate Agreements: Certain covered products in accordance with Section 1927 of the Social Security Act may not be among the baseline preferred drugs identified by the State of North Dakota's Drug Use Review Board for various therapeutic classes. The state may negotiate supplemental rebate agreements that would reclassify any drug not designated as preferred in the baseline listing for as long as the agreement is in effect.

In addition, the State has the following policies for the supplemental rebate program for the Medicaid Population:

The state of North Dakota has entered into an agreement with the "Sovereign States Drug Consortium (SSCD)" Medicaid multi-State purchasing pool. In addition to collecting supplemental rebates for fee-for-service claims, the state may, at its option, also collect supplemental rebates for Medicaid member utilization through MCO(s) under an agreement. Funds received from supplemental rebate agreements will be reported to CMS.

The state will remit the federal portion of any supplemental rebates collected. Manufacturers with supplemental rebate agreements are allowed to audit utilization data.

A rebate agreement between the state and a drug manufacturer for drugs provided to the Medicaid program, submitted to the Centers for Medicare & Medicaid Services (CMS) on September 30, 2015 and entitled, "SSDC North Dakota Medicaid Supplemental Rebate Agreement" has been authorized by CMS.

This Agreement may not be amended or modified without the mutual written consent of the parties. Any modification or amendment must be authorized by CMS.

The unit rebate amount is confidential and cannot be disclosed in accordance with Section 1927 (b)(3)(D) of the Social Security Act.

The Medical Services Division may require prior authorization for covered outpatient drugs. Non-preferred drugs are available with prior authorization.

The prior authorization process for covered outpatient drugs will conform to the provisions of Section 1927 (d)(5) of the Social Security Act.

5. Erectile dysfunction drugs will not be allowed for payment.
6. The early refill threshold for non-controlled substance prescriptions is 80%. This can be over-ridden by the pharmacist if:
  - a. They determine it is medically necessary to over-ride the early refill edit; and
  - b. The previous prescription is 50% utilized or more; and
  - c. The pharmacist submits the necessary over-ride codes.

The early refill threshold for controlled substance prescriptions is 85%. Pharmacists must contact Medical Services to discuss medical necessity for controlled substance prescription early refills as well as any non-controlled substance prescriptions that don't meet all three of the above conditions.

Accumulation edits allow a maximum of 10 days of supply accumulation in a rolling six month period for controlled substances and a maximum of 15 days of supply accumulation in a rolling six month period for non-controlled substances. Pharmacists must contact Medical Services to discuss medical necessity for over-rides for accumulation edits.

7. To increase the cost-effectiveness of dispensing habits, quantities of medication may be restricted if the Medical Services Division or the Drug Utilization Review (DUR) Board determines (a) an alternate method of dispensing would be medically appropriate and more cost-effective, or (b) the dose is not a medically accepted dose supported by citations in the compendia described in Section 1927(g)(1)(B)(i) of OBRA '93.
8. Effective January 1, 2006, the Medicaid agency will not cover any Part D drug for full-benefit dual eligible individuals who are entitled to receive Medicare benefits under Part A or Part B.

The Medicaid agency provides coverage (as specified below) for the following excluded or otherwise restricted drugs or classes of drugs, or their medical uses to all Medicaid